Tratamiento médico de 44 pacientes con carcinoma del conducto anal. Intergrupo Argentino para el Tratamiento de los Tumores Gastro-Intestinales (IATTGI) / [Medical treatment of 44 patients with anal canal carcinoma. Argentinian Intergroup for the treatment of gastrointestinal tumors (IATTGI)]

In order to investigate the medical treatment of anal canal carcinoma (ACC), 27 patients (pts) were treated with cisplatin, fluorouracil and radiotherapy, in an alternating schedule. Eleven pts received mitomycin C, fluorouracil and radiotherapy, in a concurrent scheme. Finally, six pts were included in a new outpatient scheme with cisplatin, fluorouracil, leucovorin, mitomycin C and concurrent radiotherapy. Within the first schedule, 25 pts were evaluable and 18 achieved complete response. All of them are disease free until now. With the second scheme, 7/10 pts had a complete response and 5 of them are alive and disease free. All the pts included in the last schedule (6/6) achieved complete remission. There were no deaths related to toxicity. Our experience is one of the earliest in oncology using cisplatin as a first line drug, in the non-surgical treatment of ACC. We think that the use of cisplatin is feasible, its toxicity is manageable, and its effectivity is similar to other schedules, as observed in our last scheme.

Leiomiosarcoma gastrico en la adolescencia: a proposito de un caso; revision del tema / Gastric leiomyosarcoma in adolescence: apropos of a case; review of the literature

We present the clinical case of a 16 year old patient with an "epithelloid leiomyoarcoma" (malignan leiomyoblastoma) diagnosis. Taking into consideration the rarity of this diagnosis in this age group, we review this case from the clinical and bibliographic point of view

Tratamiento del cancer avanzado de colon y recto con la asociacion de 5-fluorouracilo, imidazol carboxamida y vincristina. / Treatment of advanced cancer of the colon and rectum with the combination of 5-fluorouracil, imidazolecarboxamide and vincristine

Veintiocho pacientes portadores de cancer avanzado de colon y recto fueron tratados con el esquema FDV, consistente en suministrar el siguiente plan de tratamiento: 5-fluorouracilo 600 mg/m2 iv, dias 1 a 5; DTIC 180 mg/m2 iv, dias 1 a 5 y vincristina 1.4 mg/m2 iv, dia 1. Todo se repite cada 4 semanas. Los pacientes eran virgenes de tratamiento quimioterapico desde el comienzo de su enfermedad diseminada. Se registraron 11/28 (39,3%) respuestas objectivas mayores del 50%. La sobrevida media fue de 12 meses: 19 en respondedores y 9 en no respondedores. La toxocidad se puso de manifiesto por nauseas y vomitos: 85.7% leucopenia (inferior a 2500 granulocitos por mm3) 21%, alopecia: 28% y neuritis:14